Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
RANDOMIZED CONTROLLED TRIAL
Carole Fakhry, Qiang Zhang, Phuc Felix Nguyen-Tan, David Rosenthal, Adel El-Naggar, Adam S Garden, Denis Soulieres, Andy Trotti, Vilija Avizonis, John Andrew Ridge, Jonathan Harris, Quynh-Thu Le, Maura Gillison
PURPOSE: Risk of cancer progression is reduced for patients with human papillomavirus (HPV) -positive oropharynx cancer (OPC) relative to HPV-negative OPC, but it is unknown whether risk of death after progression is similarly reduced. PATIENTS AND METHODS: Patients with stage III-IV OPC enrolled onto Radiation Therapy Oncology Group trials 0129 or RTOG 0522 who had known tumor p16 status plus local, regional, and/or distant progression after receiving platinum-based chemoradiotherapy were eligible for a retrospective analysis of the association between tumor p16 status and overall survival (OS) after disease progression...
October 20, 2014: Journal of Clinical Oncology
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
